The global aneurysmal subarachnoid hemorrhage drugs market size was reached at $323.51 million in 2020, and is projected to surpass $456.31 million by 2030, growing at a CAGR of 3.6% from 2021 to 2030.
The global aneurysmal subarachnoid hemorrhage drugs market size was reached at $323.51 million in 2020, and is projected to surpass $456.31 million by 2030, growing at a CAGR of 3.6% from 2021 to 2030.
Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening type of stroke caused by bleeding in the area around the brain. The major factors that drive the growth of the global aSAH drugs market include surge in geriatric population and increase in population suffering from hypertension. Furthermore, lifestyle changes such as alcohol consumption and smoking increase risk of aSAH, which, in turn, propel the market growth.
Full Report is Ready | Request Sample of This Report @ https://qyresearchmedical.com/sample/112647
Hypertension is one of the major factors that can lead to aSAH. As per the Centers for Disease Control and Prevention, about 70.0 million American adults suffer from high blood pressure, of which the condition of only 52.0% is under control. Moreover, according to the Centers for Medicare and Medicaid Services the U.S. healthcare expenditures grew from 4.6% to $3.8 trillion in 2019 and accounted for 17.7% of gross domestic product (GDP). In addition, the federal government accounted for 29 % of total health expenditures, followed by households with 28.4%. State and local governments accounted for 16.1% of total health care expenditures, while other private revenues accounted for 7.5%.
Furthermore, incidence of high blood pressure has increased, costing the U.S. $46.0 billion annually, which include the cost of healthcare services, medications to treat high blood pressure, and missed days of work.
Scope of the Report
| Report Coverage | Details |
| Market Size in 2020 | $323.51 Million |
| Revenue Forecast by 2030 | $456.31 Million |
| CAGR | 3.6% from 2021 to 2030 |
| Base Year | 2021 |
| Forecast Data | 2022 to 2030 |
In addition, increase in prevalence diseases such as stroke and hypertension and surge in geriatric population drive the growth of the aSAH drugs market. In addition, lifestyle changes, including increase in alcohol consumption and smoking rise the risk for aSAH, which, in turn, stimulates the market growth.
However, the associated side effects of drugs and medication taken during the treatment of aSAH restrain the aSAH drugs market share.
Full Report is Ready | Quick Buy This Premium Report From Here: https://qyresearchmedical.com/report/checkout/112647/2900
The aSAH drugs market is segmented on the basis of drug class and region. On the basis of drug class, the market is classified into opioid analgesic, calcium channel blocker, anticonvulsants, stool softeners, osmotic agents/diuretics, and other drugs. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA
Depending on drug class, the calcium channel blocker segment dominated the market and is expected to continue this trend during the forecast period, owing to increasing prevalence rate of cardiovascular diseases, changing lifestyle and hypertension. Rising assistance to people with anxiety disorders or bipolar disorder is also expected to help in the growth of the aneurysmal subarachnoid hemorrhage drugs market. In addition, increase patient awareness level, availability of the treatment options and vulnerable geriatric population are some of the influencing factors propelling the growth of the calcium channel blocker aSAH drugs market growth.
Region wise, North America dominated the market in 2020, owing to favorable healthcare infrastructure, which facilitated access to advanced aSAH drugs. In addition, government initiatives, including the Precision Medicine and Affordable Care Act, along with well-planned reimbursement policies, contributed to the market growth in North America. Moreover, surge in awareness among people and high purchasing parity resulted in increased demand for these devices. However, Asia-Pacific is expected to witness considerable market growth during the forecast period, due to rise in government support to enhance healthcare infrastructure. Economic developments in countries, including India and China, with higher disposable incomes fuel the demand for product. Moreover, China is expected to grow at high CAGR in, thereby making Asia-Pacific aaSAH drugs market opportunity.
The major companies profiled in this report include Azurity Pharmaceuticals, Johnson & Johnson, MediCure, NeurOp, Orexo AB, Pfizer, Inc., Pharmaxis, Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vitrais, Inc.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current aSAH drugs market trends, estimations, and dynamics of the aneurysmal subarachnoid hemorrhage drugs market analysis from 2020 to 2030 to identify the prevailing aneurysmal subarachnoid hemorrhage drugs market opportunities.
- The aSAH Drugs Market analysis research is offered along with information related to key drivers, restraints, and opportunities.
- Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the aneurysmal subarachnoid hemorrhage drugs market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global aSAH drugs industry trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
- By Drug Class
- Calcium Channel Blocker
- Anticonvulsant
- Stool Softener
- Osmotic Agents/Diuretics
- Other Drugs
- Opioid Analgesic
- By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Turkey
- South Africa
- Rest of LAMEA
- North America
Key Market Players
- Azurity Pharmaceuticals
- Johnson and Johnson
- medicure
- NeurOp
- orexoab
- Pfizer, Inc.
- Pharmaxis, Ltd.
- Sun Pharmaceutical Industries Ltd.
- teva pharmaceutical industries ltd.
- Vitrais, Inc
Full Report is Ready | Quick Buy This Premium Report From Here: https://qyresearchmedical.com/report/checkout/112647/2900
You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333
About Us
QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.
For Latest Update Follow Us:
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/